<DOC>
	<DOC>NCT01576380</DOC>
	<brief_summary>This is a prospective, open-label, single-arm, non-randomized, multi-center, phase II proof of concept (PoC) study with a two-stage design and Bayesian interim monitoring to evaluate efficacy and safety of single agent TKI258 in adult patients with scirrhous gastric carcinoma (SGC) that have progressed after one or two prior systemic treatments.</brief_summary>
	<brief_title>A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Neoplasms by Site</mesh_term>
	<mesh_term>Stomach Diseases</mesh_term>
	<mesh_term>Adenocarcinoma, Scirrhous</mesh_term>
	<mesh_term>Linitis Plastica</mesh_term>
	<criteria>Diagnosis of advanced/metastatic scirrhous gastric carcinoma Evidence of diffusely infiltrating gastric lesions and/or at least one measurable extragastric lesion Patients previously treated with one or two systemic lines Documented radiological confirmation of disease progression ECOG performance status of 0 to 2 Male and female patients aged 20 years or greater Adequate liver, renal, and hematologic function Patients who received prior treatment with an FGFR inhibitor Patients with known brain metastases or who have signs/symptoms attributable to brain metastases and have not been assessed with radiologic imaging to rule out the presence of brain metastases Patients with another primary malignancy within 3 years prior to starting study treatment Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Solid tumors</keyword>
	<keyword>Advanced scirrhous gastric carcinoma</keyword>
	<keyword>Gastric Cancer</keyword>
	<keyword>Second-line or third-line treatment</keyword>
	<keyword>VEGF</keyword>
	<keyword>FGFR</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Gastric Neoplasms</keyword>
	<keyword>Cancer</keyword>
	<keyword>Carcinoma</keyword>
	<keyword>Gastric Diseases</keyword>
	<keyword>Female Genital Diseases</keyword>
	<keyword>Tumors</keyword>
	<keyword>Oral Administration</keyword>
	<keyword>Capsules</keyword>
	<keyword>TKI258</keyword>
	<keyword>TKI-258</keyword>
	<keyword>TKI 258</keyword>
</DOC>